SC
Sureschandra Chimanlal Kagadada
About Sureschandra Chimanlal Kagadada
Data last updated:
Sureschandra Chimanlal Kagadada has 10 years in corporate governance. Holds Director role. Currently with 1 company, including N-Vascular Technology Private Limited. Engaged in Technology. Contributes to corporate operations. The largest current company by reported revenue is N-Vascular Technology Private Limited at ₹33.50 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 21 Jun 2016 | 2016 | ₹33.50 Cr (FY 2025) | Active |
Previous companies
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Sureschandra Chimanlal Kagadada
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sureschandra Chimanlal Kagadada
Sureschandra Chimanlal Kagadada has 10 years in corporate governance. Holds Director role. Currently with 1 company, including N-Vascular Technology Private Limited. Engaged in Technology. Contributes to corporate operations. The largest current company by reported revenue is N-Vascular Technology Private Limited at ₹33.50 Cr (FY 2025).
Sureschandra Chimanlal Kagadada is associated with 1 company as Director, including N-Vascular Technology Private Limited (₹33.50 Cr).
Sureschandra Chimanlal Kagadada has expertise in Technology.
Sureschandra Chimanlal Kagadada has 10 years in corporate governance.
By reported revenue, the largest current company of Sureschandra Chimanlal Kagadada is N-Vascular Technology Private Limited, with revenue of ₹33.50 Cr (FY 2025).
Sureschandra Chimanlal Kagadada currently holds positions at 1 company: N-Vascular Technology Private Limited (₹33.50 Cr).